Current research on triple-negative breast cancer includes anti-tumor-related pathways against IGF1 [24], promotion of tumor cell death [25], and targeting the IGF-1/IGF-1R signaling axis for the treatment of TNBC [26]. This evidence concerns the gene IGF1R and triple-negative breast carcinoma.